PREDICATE,SUBJECT_NAME,OBJECT_NAME,Factuality_Score,Cancer_Type
DIAGNOSES,Microlaryngoscopy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Positron-Emission Tomography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Early Diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Spectrum Analysis, Raman",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Core needle biopsy,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Assay,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Author,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Needle biopsy procedure,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Immunohistochemistry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Author,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Fluorescent in Situ Hybridization,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Toxicology screen, general",Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Microarray Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,CK2,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Cytokeratin-8 Staining Method,Breast cancer stage III,0.0029970029970029,Female Breast Cancer
DIAGNOSES,HIGH SENSITIVITY,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Scanning,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Correlation Study,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Lymphography,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,IMMUNOHISTOCHEMICAL,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Immunohistochemistry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Medical pathologist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,single cell analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,radiologist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Treatment Protocols,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Sentinel Lymph Node Biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Nurses,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Enzyme-Linked Immunosorbent Assay,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,fluorodeoxyglucose positron emission tomography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Platelet Count measurement,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,Physicians,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Biopsy,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Mucin-1 Staining Method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,diagnostic procedure,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,Fluorescence Spectroscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Radioisotope scan of lymphatic system,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Genetic screening method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Research Personnel,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Liver Function Tests,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Fine needle aspiration biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Core needle biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Cell marker,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Medical Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Immunohistochemistry,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Transbronchial lung biopsy,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,IMMUNOHISTOCHEMICAL,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Total protein measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,diagnostic procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Autoantibody response,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Fine needle aspiration biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Polymerase Chain Reaction,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Image analysis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Liquid Chromatography Mass Spectrometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Densitometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Radiometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Activated clotting time measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,thermography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Sample analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Flow Cytometry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,In Situ Hybridization,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Needle biopsy procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Surgeon,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Assay,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Lymphocyte Count,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Radionuclide Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Ultrasonography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Molecular Diagnosis,Familial cancer of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Plasma prolactin,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,rapid technique,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Mass Screening,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,disease stage,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Research Personnel,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,In Situ Hybridization,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Anti-thyroid antibody measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,In Situ Hybridization,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Diagnostic Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Author,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,"Glucose-6-phosphate dehydrogenase measurement, quantitative",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Mammography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Drill biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Immunofluorescence,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Soft Agar Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Morphometric analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Assay,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,Morphometric analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Histocytochemistry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Immunoblotting,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Immunocytochemistry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Radionuclide Imaging,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Flow Cytometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Enzyme Immunoassay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Cytology examination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Antibody to islet cells of pancreas measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diaphanography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Plasma oestradiol,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Estradiol measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,IMMUNOHISTOCHEMICAL,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diagnostic Neoplasm Staging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Self-Examination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Galactography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Clinical Research,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Spectrum Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Palpation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Enzyme Immunoassay,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Biopsy,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,IMMUNOHISTOCHEMICAL,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Morphometric analysis,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
MEASURES,Analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Lymphography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Chromatography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Radioimmunoassay,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer
DIAGNOSES,Cell Culture Techniques,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Microscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Adsorption,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Histocytochemistry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Breast Self-Examination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Sensitivity test,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Radioisotope scan of lymphatic system,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Image analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Excision biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Immunoperoxidase Techniques,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Preservation, Biological",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Lipids measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Protein profiling,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diagnostic radiologist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Examination of breast,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Surgical biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,CALCULATION,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,thermography,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer
DIAGNOSES,mutation analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Flow Cytometry,Breast cancer stage II,0.0,Female Breast Cancer
DIAGNOSES,Mammography,bilateral breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Xeromammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,DNA analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
MEASURES,Clinical Research,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Cytometry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Antigen assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Ultrasonography,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Excision biopsy,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Differential Diagnosis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
MEASURES,"Spectroscopy, Nuclear Magnetic Resonance",Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Diagnostic radiologic examination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,fluorodeoxyglucose positron emission tomography,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Immunoradiometric Assays,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Cytodiagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Genetic Screening,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Immunohistochemistry,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Transillumination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Mammography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
MEASURES,Case-Control Studies,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,mutation analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Doppler Ultrasound,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Image analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Clinical Trials Data Monitoring Committees,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Polymerase Chain Reaction,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Breast thermography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Cytogenetic procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,friend,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,HIGH SENSITIVITY,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Family,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Ultrasonography,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Core needle biopsy,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Fluorescent in Situ Hybridization,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Endosonography,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer
DIAGNOSES,"Blotting, Western",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,HIGH SENSITIVITY,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
MEASURES,Enzyme-Linked Immunosorbent Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Breast Self-Examination,Familial cancer of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Technologist NOS,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Clinicians,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Pre-surgery evaluation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Microscopy, Immunoelectron",Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
MEASURES,Magnetic Resonance Imaging,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Chromosome Mapping,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Scanning,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Fine needle aspiration biopsy,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
MEASURES,Chromogenic in situ Hybridization,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Sentinel Lymph Node Biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
MEASURES,logistic regression analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Excision biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Osteopontin Staining Method,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Research Personnel,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Electrophoresis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Toxicology screen, general",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Digital mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Genetic screening method,bilateral breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Neutralising antibodies,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Assay,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Fine needle aspiration biopsy,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Biopsy,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,"Spectrometry, Mass, Electrospray Ionization",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Cancer Diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,"Blotting, Western",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Validation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Health Personnel,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Microscopy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Immunocytochemistry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,chromatin immunoprecipitation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Immunohistochemistry,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Genotype determination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Excision biopsy,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer
DIAGNOSES,DNA analysis,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Biopsy,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,Gene Expression Profiling,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Tomography, Emission-Computed",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Spectrum Analysis, Mass",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Dot Immunoblotting,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Medical oncologist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Dilution,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Weighing patient,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Medical pathologist,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,"Microscopy, Electron, Scanning",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Computed Tomographic Colonography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Liquid Chromatography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Metabolic analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,breast cancer diagnosis,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Prostate specific antigen measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diffusion Magnetic Resonance Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Health Personnel,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Blood cadmium measurement,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Author,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,High Throughput Screening,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Ultrasonography,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,DNA analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Differential white blood cell count procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Sequence Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Tomography, Optical",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Core needle biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Western Blot,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Reader,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Activated clotting time measurement,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,athlete,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Actor,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Enzyme-Linked Immunosorbent Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Spectroscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,2D Polyacrylamide Gel Electrophoresis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Western Blot,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
MEASURES,simulation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Cell hybridization,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Biopsy,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,tomography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Western Blot,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Immunoassay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,Contralateral breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Incisional biopsy - action,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Core needle biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Histology Procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Fine needle aspiration biopsy,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,Sentinel Lymph Node Mapping,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Mucin-1 Staining Method,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Ultrasonography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Fluorescent in Situ Hybridization,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Sentinel Lymph Node Mapping,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,diagnostic procedure,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,fluorodeoxyglucose positron emission tomography,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,Functional assessment,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Mammography,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,endoscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Cytokeratin-14 Staining Method,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
MEASURES,Magnetic Resonance Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Polymerase Chain Reaction,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Fine needle aspiration biopsy,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Sentinel Lymph Node Biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Polymerase chain reaction analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Reporter,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Laser Scanning Cytometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Primary Care Physicians,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Tomography, Emission-Computed, Single-Photon",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Flow Cytometry,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
MEASURES,Assay,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,Author,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Immunophenotyping,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Beck depression inventory,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diagnostic tests,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Tumor Burden,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Immunohistochemistry,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Administrators,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
MEASURES,Fluorescent in Situ Hybridization,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Differential Diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Incisional biopsy - action,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Fluorescent in Situ Hybridization,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Sentinel Lymph Node Mapping,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Serologic tests,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Chest CT,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Serum estradiol measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Immunodiagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Needle biopsy procedure,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Cell marker,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Ultrasonography,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
MEASURES,Magnetic Resonance Imaging,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Diagnostic tests,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Tumor Burden,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Chest imaging,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,genetic analysis,Familial cancer of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Mucin-2 Staining Method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Palpation,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,Serum selenium,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Immunophenotyping,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Enzyme-Linked Immunosorbent Assay,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,student,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Computed Tomographic Colonography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Endoscopy of nose,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Cell marker,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer
DIAGNOSES,tomography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Nucleic acid assay,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Fine needle aspiration biopsy,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer
DIAGNOSES,IMMUNOHISTOCHEMICAL,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Triple test,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Androgens measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Sentinel Lymph Node Biopsy,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,Stereo microscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Mammography,Carcinoma in situ of breast,0.0,Female Breast Cancer
DIAGNOSES,Cell hybridization,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Measurement of serum lipid level,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Mammography,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Molecular Diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Breast Cancer Surveillance Consortium,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,"Interview, Psychological",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,In Situ Hybridization,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Tomography, Emission-Computed",Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
MEASURES,Immunohistochemistry,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Air steward,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Diagnosis, Fluoroscopic",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Blood typing procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Minimum Inhibitory Concentration measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Gene Expression Profiling,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Gene Expression Profiling,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,DNA stability,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,"Tomography, Emission-Computed",Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
MEASURES,Early Diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,clonality,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Polymerase Chain Reaction,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,breast cancer diagnosis,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Quantitative Microscopy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Nucleic acid assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Microarray Analysis,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Screening Examination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Body mass index procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,COMPUTED,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Medical practitioners NOS,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Computerized tomography, 3 dimensional reconstruction",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Medical Imaging,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Differential Diagnosis,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Caregiver,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Computed Tomographic Colonography,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Culture Techniques,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Digital Image Analysis,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Medical Imaging,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Positron-Emission Tomography,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,"Tomography, Emission-Computed",Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Immunohistochemistry,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Puncture biopsy,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Gene Expression Profiling,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Pathology procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Fluorescent Antibody Technique,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,PET/CT scan,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,BRCA Mutation Analysis,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Scintimammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Contrast-enhanced Magnetic Resonance Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Digital Breast Tomosynthesis,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
MEASURES,one-step nucleic acid amplification,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Mammography,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,"Spectroscopy, Fourier Transform Infrared",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Pathologic Examination,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Psychometrics,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,College of American Pathologists,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Assay,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Quantitative PCR analysis,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,FDG-Positron Emission Tomography and Computed Tomography Scan,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
MEASURES,Western Blotting,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Sentinel Lymph Node Biopsy,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Liquid Biopsy,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Digital Breast Tomosynthesis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Computer Assisted Diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Lactate dehydrogenase measurement,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Diffusion weighted imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Gene Expression Profiling,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Screening procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,S-Phase Fraction,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Cell Count,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diagnosis,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Assay,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Single-Cell Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Medical pathologist,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Laboratory Procedures,Recurrent Breast Carcinoma,0.0019980019980019,Recurrent Breast Cancer
DIAGNOSES,Cell Count,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Microwave Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Breast Cancer Surveillance Consortium,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Optical Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Assessment: Cognition,Breast cancer stage III,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,Papillary carcinoma of the breast,0.0009990009990009,Female Breast Cancer
DIAGNOSES,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Biomarker Analysis,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Breast Cancer Type 1 Susceptibility Protein Measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Immunohistochemistry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Breast Cancer Type 1 Susceptibility Protein Measurement,Sporadic Breast Carcinoma,0.0009990009990009,Female Breast Cancer
DIAGNOSES,Ki67 Measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Sentinel Lymph Node Biopsy,Papillary carcinoma of the breast,0.0009990009990009,Female Breast Cancer
DIAGNOSES,Diagnosis,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,peripheral blood profile,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Contrast enhanced spectral mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,thermal imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Magnetic resonance imaging of breast,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Dermatologist,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Body mass index procedure,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Ultrasonography,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,FDG-Positron Emission Tomography,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,tomosynthesis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,FDG-Positron Emission Tomography and Computed Tomography Scan,Recurrent Breast Carcinoma,0.0019980019980019,Recurrent Breast Cancer
DIAGNOSES,Radioisotope scan of bone,Recurrent Breast Carcinoma,0.0019980019980019,Recurrent Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Color doppler ultrasound,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Microscopy,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Ultrasonography,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Laboratory Procedures,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diagnosis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Methionine measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Digital Mammography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,"Breast Cancer, Familial",0.0049950049950049,Female Breast Cancer
DIAGNOSES,Breast Cancer Type 1 Susceptibility Protein Measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Multiparametric Magnetic Resonance Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Genetic screening method,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Diffusion weighted imaging,contralateral breast cancer,0.0,Female Breast Cancer
DIAGNOSES,Diffusion weighted imaging,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Lymphangiography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Digital Mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Clinician,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Ultrasonography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Magnetic resonance imaging of breast,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Formalin-Fixed Paraffin-Embedded,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Parametric Image,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Contrast-Enhanced Mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Laboratory Procedures,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,High-B-Value Diffusion-Weighted Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Breast Cancer Type 1 Susceptibility Protein Measurement,"Breast Cancer, Familial",0.0049950049950049,Female Breast Cancer
DIAGNOSES,Transient elastography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Positron-Emission Tomography,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Single-Cell Analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Cell phenotype determination procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Contrast-Enhanced Ultrasound,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Microscopy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Image-Guided Biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Magnetic resonance imaging of breast,contralateral breast cancer,0.0,Female Breast Cancer
DIAGNOSES,Core needle biopsy,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
MEASURES,Colorimetric Cell Viability Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Liquid Biopsy,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Fibrinogen to Albumin Ratio Measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Assay,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Upstaging,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Ki67 Measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Biopsy,Secondary malignant neoplasm of breast,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Core needle biopsy,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Sentinel Lymph Node Biopsy,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Immunohistochemistry,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,PET/CT scan,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Genetic screening method,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer
DIAGNOSES,FDG-Positron Emission Tomography and Computed Tomography Scan,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Research Personnel,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Assay,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Sentinel Lymph Node Biopsy,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Subtyping,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Screening Method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,PET/CT scan,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Ki67 Measurement,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Magnetic resonance imaging of breast,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,radiologist,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Immunohistochemistry,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Ultrasound-Guided Core Biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,B mode ultrasound,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Diffusion weighted imaging,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Immunophenotyping,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,"Ultrasonography, Mammary",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diagnosis,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Screening procedure,"Breast Cancer, Familial",0.0049950049950049,Female Breast Cancer
DIAGNOSES,"Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization",Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
MEASURES,Study,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Electrocorticogram,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Early Diagnosis,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Laboratory Procedures,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
MEASURES,Ultrasonography,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Health Personnel,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Microarray Analysis,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Biomarker Analysis,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,tomography,Recurrent Breast Carcinoma,0.0019980019980019,Recurrent Breast Cancer
DIAGNOSES,Breast Cancer Type 1 Susceptibility Protein Measurement,Carcinoma breast stage I,0.0,Female Breast Cancer
DIAGNOSES,Contrast-enhanced Magnetic Resonance Imaging,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Computed Tomography (CT) of Liver,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Spectroscopy, Fourier Transform Infrared",Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Fecal analysis procedure,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Diagnosis,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Fibrin-fibrinogen split products assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Screening procedure,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Diagnosis,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,fMRI,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Infrared Thermography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Immunophenotyping,Luminal B Breast Carcinoma,0.0039960039960039,Female Breast Cancer
DIAGNOSES,Multiparametric Magnetic Resonance Imaging,contralateral breast cancer,0.0,Female Breast Cancer
DIAGNOSES,Absolute Reticulocyte Count,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Single-Cell Analysis,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,Single-Cell Analysis,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Immunohistochemistry,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Magnetic resonance imaging of breast,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Biopsy,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Cell Count,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Cytometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Mass Spectrometry,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Vacuum assisted biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Laboratory Procedures,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Imaging Techniques,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Digital Image Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Research Personnel,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Digital Image Analysis,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Volume Measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Biopsy,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,PET/CT scan,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Platelet hematocrit measurement,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Ultrasonography,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Photoacoustic Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,T2 (Observed)-Weighted Imaging,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Subtyping,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Radionuclide Imaging,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,clonality,Contralateral breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,mutation analysis,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Immunoprecipitation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Immunofluorescence,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Excision biopsy,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Endoscopic biopsy,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Cytokeratin-18 Staining Method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Logistic Regression,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Hair zinc,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Western Blot,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Homocysteine level,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Iodine uptake,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,DERIVED,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Functional Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,White Blood Cell Count procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,angiogram,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Xeroradiography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Spectrum Analysis, Raman",Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Diagnostic Neoplasm Staging,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Immunocytochemistry,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Estrogen receptor assay (ERA),Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,"Spectrum Analysis, Raman","Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,"Spectrum Analysis, Raman","Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,"Cloning, Molecular",Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Microdissection,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Immunoperoxidase Techniques,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Image analysis,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Nucleic acid assay,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Mediastinoscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Ultrasonography,bilateral breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Surgeon,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Estrogen receptor assay (ERA),Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Staining method,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,Progesterone receptor assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Morphometric analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,histological diagnosis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Early Diagnosis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Incisional biopsy - action,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,DNA chemical synthesis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,General Practitioners,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diaphanography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Clinical Trials,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Author,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,histological diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Carbohydrate antigen 549 measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Radioimmunodetection,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Spectrometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Lymphography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Venography - procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,thermography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Diagnostic radiologic examination,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Puncture biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Radioisotope scan of bone,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Chromatography, Affinity",Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Mucin-1 Staining Method,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Mucin-2 Staining Method,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Optical Methods,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,DIRECT ASSAY,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Surgeon,Familial cancer of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Sequence Determinations,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Estrogen measurement,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Voluntary Workers,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Sentinel Lymph Node Biopsy,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Skeletal X-ray,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Pilot,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Ultrasonography,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
MEASURES,Enzyme Immunoassay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Nuclear medicine procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Research Personnel,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Mucin-2 Staining Method,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Woman,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Enzyme Immunoassay,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Mammography,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,mutation analysis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Mucin-1 Staining Method,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Hormone measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Creatinine clearance measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Cell Count,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,"Ultrasonography, Doppler, Color",Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Oncologist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,WORK UP,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Histocytochemistry,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,genetic analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Tomography, Spiral Computed",Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,small angle X ray scattering,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Positron-Emission Tomography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Incisional biopsy - action,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,immunological status,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Plasma insulin,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,HIGH SENSITIVITY,Contralateral breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Colposcopy,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,high throughput analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Exploration with a probe,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Hepatitis B virus DNA assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Plasma estradiol measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Weighing patient,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Gene Expression Profiling,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Mammography,Familial cancer of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,"Spectrum Analysis, Mass","Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Abdomen scan,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,molecular imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Patients,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Pathologist evaluation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Insulin-like growth factor binding protein 3 level,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Plain x-ray,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Morphometric analysis,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Clinicians,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,Laboratory studies,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,"Tomography, Emission-Computed",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Cell marker,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Core needle biopsy,bilateral breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Needle biopsy procedure,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
MEASURES,Ultrasonography,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,HIGH SENSITIVITY,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Clinicians,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Gene Expression Profiling,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
MEASURES,Mammography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,fluorodeoxyglucose positron emission tomography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Biopsy,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer
DIAGNOSES,CD4/CD8 ratio procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Provider,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,AIDS diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,mutation analysis,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Medical oncologist,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,"Microscopy, Confocal",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Core needle biopsy,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Immunology profile,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Hemoglobin measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Tomography, Emission-Computed","Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
MEASURES,Core needle biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diagnostic radiologic examination,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,fluorodeoxyglucose positron emission tomography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,IMMUNOHISTOCHEMICAL,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Hospital specialist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Lymph Node Mapping,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Toxicology screen, general",Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,HercepTest,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Plastic surgeon,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,intravital microscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Ultrasonography, Doppler, Color",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diagnostic tests,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Surgical biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Patients,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Estimator,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,BREAST.FINE NEEDLE,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Nurses,Familial cancer of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Palpation,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
MEASURES,Clinical Trials,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Biopsy,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,"Toxicology screen, general",Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Histology Procedure,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Needle biopsy procedure,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Diagnostic Neoplasm Staging,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Autopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Immunophenotyping,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Author,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,Mammography,Contralateral breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Mammography,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
MEASURES,Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Cancer antigen 27.29,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Ultrasonography,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,tomography,Contralateral breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Osteopontin Staining Method,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Cytokeratin-14 Staining Method,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Immunophenotyping,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,breast cancer diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Tomography, Ultrasonic",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diagnostic radiologic examination,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,"Tomography, Emission-Computed",Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,Scanning,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Pulmonary function tests,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Molecular Diagnostic Testing,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Cell hybridization,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,fluorodeoxyglucose positron emission tomography,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Teacher,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Amino acid level,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Multimodal Imaging,bilateral breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Mammography,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,Cell marker,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Positron-Emission Tomography,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,"Microscopy, Scanning Tunneling",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Flow Cytometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Immunohistochemistry,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Sodium measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Ultrasonography,Contralateral breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,HIGH SENSITIVITY,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
MEASURES,Fine needle aspiration biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Sentinel Lymph Node Biopsy,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,Breast cancer stage III,0.0029970029970029,Female Breast Cancer
DIAGNOSES,rapid diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Blood Tests,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,proteomic profiling,Familial cancer of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,"Sequence Analysis, RNA",Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Author,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Endocrine studies,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
MEASURES,Social Aspects of Cancer,Familial cancer of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Principal Investigator,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Attending,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Bone density scan,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Examination of breast,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Sodium measurement,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
MEASURES,Mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Computed Tomographic Colonography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,tomography,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
MEASURES,explanation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,IMMUNOHISTOCHEMICAL,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Cell marker,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,breast cancer diagnosis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Histology Procedure,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Gynecologist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Author,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
MEASURES,diagnostic procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,Familial cancer of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Estimator,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,X-Ray Computed Tomography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Hematocrit procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Spectroscopy, Near-Infrared",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Mucin-2 Staining Method,Mucinous breast cancer,0.0009990009990009,Other
MEASURES,Interview,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Early Diagnosis,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
MEASURES,Core needle biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,"Toxicology screen, general",Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Steroid hormone measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Professional guide,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,tailor,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Multimodal Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Cone-Beam Computed Tomography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,scholar,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Cytological Techniques,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
MEASURES,Immunohistochemistry,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Positron Emission Tomography and Magnetic Resonance Imaging,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Consultant surgeon,Stage III Breast Cancer AJCC v6,0.0,Other
DIAGNOSES,Mammogram - symptomatic,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,saliva analysis,Stage 0 Breast Cancer AJCC v6 and v7,0.0,Female Breast Cancer
DIAGNOSES,Cytological Techniques,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Liquid Biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diagnosis,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,professional occupation status,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Computer Assisted Diagnosis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,nipple discharge cytology,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Clinician,"Breast Cancer, Familial",0.0049950049950049,Female Breast Cancer
DIAGNOSES,Screening procedure,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Author,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,FDG-Positron Emission Tomography and Computed Tomography Scan,malignant neoplasm of breast staging,0.0,Female Breast Cancer
DIAGNOSES,Differential panel,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Western Blotting,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Transient elastography,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Contrast used,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Scientific Study,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Spectrum Analysis, Raman",Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Positron-Emission Tomography,HER2-negative breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Immunohistochemistry,Sporadic Breast Carcinoma,0.0009990009990009,Female Breast Cancer
MEASURES,Immunohistochemistry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Assay of volatiles,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Chest CT,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Western Blot,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Positron-Emission Tomography,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Spectroscopy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Screening procedure,Basal-Like Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Positron-Emission Tomography,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,MRI guided biopsy,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Serum gamma-glutamyl transferase measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Alpha tumour necrosis factor measurement,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Cell Count,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
MEASURES,Real-Time Polymerase Chain Reaction,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Ki67 Measurement,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Contrast enhanced spectral mammography,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Mammography,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Liquid Biopsy,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Chemokine (C-X3-C Motif) Ligand 1 Measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Activation Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Transient elastography,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Pre-surgery evaluation,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Scientific Study,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,electrical impedance tomography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Ultrasound guided biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Biopsy,malignant neoplasm of breast staging,0.0,Female Breast Cancer
DIAGNOSES,Medical practitioner,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Dual-Energy X-Ray Absorptiometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Contrast enhanced spectral mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Tumor Burden,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Microarray Analysis,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,"Tomography, Emission-Computed",Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Pre-surgery evaluation,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Pathologic Examination,Secondary malignant neoplasm of breast,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Digital Mammography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Epidermal Growth Factor Receptor Measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Conventional Imaging,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Screening procedure,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
MEASURES,Reverse Transcriptase Polymerase Chain Reaction,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Genetic screening method,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,fluid aspiration,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Breast Self-Examination,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Ki67 Measurement,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Work-up,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Ultrasonography, Mammary",Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Superb microvascular imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Health Personnel,Malignant neoplasm of female breast,0.0,Female Breast Cancer
DIAGNOSES,Nuclear magnetic resonance imaging brain,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,"Diagnosis, clinical",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Observation - diagnostic procedure,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
MEASURES,Modeling,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Epidermal Growth Factor Receptor Measurement,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Complete Blood Count,Unilateral Breast Carcinoma,0.0,Female Breast Cancer
MEASURES,Magnetic Resonance Imaging,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Sentinel Lymph Node Biopsy,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Breast Imaging Reporting and Data System,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Formalin-Fixed Paraffin-Embedded,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Vacuum assisted biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Biological Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Digital Image Analysis,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Monocyte Chemotactic Protein 1 Measurement,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Clinician,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Breast Cancer Type 1 Susceptibility Protein Measurement,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer
DIAGNOSES,Biopsy of lymph node using ultrasound guidance,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Cell Count,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,contralateral breast cancer,0.0,Female Breast Cancer
DIAGNOSES,Core needle biopsy,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Vasoactive intestinal polypeptide measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Screening procedure,malignant neoplasm of breast staging,0.0,Female Breast Cancer
DIAGNOSES,Oncologists,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Positron-Emission Tomography,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Cryopreservation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Contrast-Enhanced Mammography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Computational analysis,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Ultrasonography,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer
DIAGNOSES,Screening procedure,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Mutation Detection,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Blood glucose measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Genetic Variation Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Scintimammography,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer
MEASURES,Contrast-Enhanced Ultrasound,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Hematoxylin and eosin stain method,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Immunohistochemistry,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Color doppler ultrasound,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Androgens measurement,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,breast imaging studies,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Cytokeratin-18 Staining Method,Carcinoma in situ of breast,0.0,Female Breast Cancer
DIAGNOSES,Medical pathologist,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Polymerase Chain Reaction,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Plasma oestrogen,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,X-Ray Computed Tomography,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Calcium measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Assay,Sporadic Breast Carcinoma,0.0009990009990009,Female Breast Cancer
DIAGNOSES,Cytogenetic procedure,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,"Cloning, Molecular",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Serum prolactin,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Electron Microscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Woman,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Electron Microscopy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Professional Organization or Group,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Antibody to islet cells of pancreas measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Immunodiffusion,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Karyometry,Breast cancer stage III,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Silver Staining,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Fluoroscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Lymphocyte subset measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Plasma lipid measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Thoracoscopy,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,"Spectroscopy, Nuclear Magnetic Resonance",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Ultrasonography, Interventional",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diagnostic radiologic examination,Tubular breast cancer,0.0009990009990009,Other
DIAGNOSES,Magnetic Resonance Imaging,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer
DIAGNOSES,Antigen test,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Fractionation,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Hormone measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Venography - procedure,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Serum prolactin,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
MEASURES,Cell Count,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Medical Imaging,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Histology Procedure,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,"Toxicology screen, general",Carcinoma in situ of breast,0.0,Female Breast Cancer
DIAGNOSES,Bone marrow biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Polarographic measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,tissue processing,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,CALCULATION,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Excision biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Leukocyte Adherence Inhibition Test,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Zinc measurement,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Research Personnel,Sporadic Breast Carcinoma,0.0009990009990009,Female Breast Cancer
DIAGNOSES,Serum C reactive protein level,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Hematology procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Puncture biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Mutagenicity Tests,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Image Cytometry,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,PO2 measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,HercepTest,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Triple test,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Positron-Emission Tomography,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,"Tomography, Emission-Computed, Single-Photon",Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Breast Cancer Surveillance Consortium,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Prostate specific antigen measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,tomography,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Mucin-1 Staining Method,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Cytotoxicity assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,HercepTest,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Parathyroid scintigraphy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Provider,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Physical activity assessment,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Fluorescent in Situ Hybridization,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Author,Sporadic Breast Carcinoma,0.0009990009990009,Female Breast Cancer
DIAGNOSES,Immunohistochemistry,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,Oncology Group,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Molecular Diagnosis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,High density lipoprotein measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,radiologist,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Faculty,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Immunoassay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Research Personnel,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,molecular imaging,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
MEASURES,tomography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,TELOMERE ANALYSIS,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Sequence Analysis, DNA",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Cancer Diagnosis,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Serum testosterone measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Blood Count, Complete",Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Assay,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Flow Cytometry,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,"Preservation, Biological",Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,IMMUNOHISTOCHEMICAL,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,Chromogenic in situ Hybridization,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,DNA ploidy analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Immunoblot Analysis,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,mutation analysis,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Serum protein profile,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Blood Count, Complete",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Breast Cancer Surveillance Consortium,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Fine needle aspiration biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Genetic Marker Expression,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Surgeon,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Assay,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Diffusion weighted imaging,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Primary Care Physicians,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Author,Breast cancer stage III,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Tissue Fixation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Flow Cytometry,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer
DIAGNOSES,Serum estradiol measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Trucut biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Subrenal Capsule Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Screening Examination,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Breast Imaging Reporting and Data System Mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,HIGH SENSITIVITY,Familial cancer of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Radionuclide Imaging,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,"Tomography, Optical",Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Cell marker,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Digital slit-beam radiograph,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Immunohistochemistry,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer
DIAGNOSES,histological diagnosis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Infertility study,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Histocytochemistry,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Clinical Trials Cooperative Group,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,"Tomography, Spiral Computed",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Blotting, Western",Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
MEASURES,Spectrum Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Vascular assessment,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Staff,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Employee,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,tomography,Breast cancer stage III,0.0029970029970029,Female Breast Cancer
MEASURES,Mass Fragmentography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Digital mammography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Immunofluorescence,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Drug measurement,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Immunoblot Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Clinical Research,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Statistician,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Maker NOS,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Family investigation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,MRI of breast,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Body mass index procedure,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Perfusion Magnetic Resonance Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Puncture biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
MEASURES,environmental factors,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Statistical Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Oxygen measurement, partial pressure, arterial",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Fine needle aspiration biopsy,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Microarray Analysis,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,"Tomography, Emission-Computed",Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Oncologist,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Radiation therapist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Whole Body Imaging,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Medical Imaging,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Paraffin Embedding,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Spinal Puncture,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,Recurrent Breast Carcinoma,0.0019980019980019,Recurrent Breast Cancer
DIAGNOSES,Core needle biopsy,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Biological Assay,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Transmission imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,CD4/CD8 ratio procedure,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Immunoassay method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,X-Ray Computed Tomography,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Chemokine (C-X-C Motif) Ligand 10 Measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Airway Resistance Test,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Biopsy of breast,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Western Blotting,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,High sensitivity,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diffuse Optical Tomography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Oncologists,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,MammaPrint,Recurrent Breast Carcinoma,0.0019980019980019,Recurrent Breast Cancer
DIAGNOSES,Pathologic Examination,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Biopsy,Breast cancer stage III,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Blood Vessel Density,Triple-Negative Breast Carcinoma,0.0,Female Breast Cancer
DIAGNOSES,Axillary Reverse Mapping,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,BRCA Mutation Analysis,contralateral breast cancer,0.0,Female Breast Cancer
DIAGNOSES,Diagnostic Neoplasm Staging,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Computed Tomography with Contrast,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,High-Throughput Screening,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Liquid Biopsy,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Fine needle aspiration biopsy,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Complete Blood Count,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,serum Fatty acid level,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,High-Throughput Nucleotide Sequencing,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Ki67 Measurement,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Noninvasive Prenatal Testing,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,methodological quality,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Assay,Mucinous breast cancer,0.0009990009990009,Other
DIAGNOSES,Screening for malignant neoplasm of lung,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Physicians,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Estimated Glomerular Filtration Rate,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Chest imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Needle biopsy procedure,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Assay,Breast cancer stage III,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Magnetic resonance imaging of breast,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Diagnosis,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Glomerular Filtration Rate,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,thermography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Fas Cell Surface Death Receptor Measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
MEASURES,Risk Analysis,contralateral breast cancer,0.0,Female Breast Cancer
DIAGNOSES,Screening procedure,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Cardiac monitoring,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Ultrasound Tomography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,PET/CT scan,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,PET/CT scan,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Observation - diagnostic procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Observation - diagnostic procedure,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Cytokeratin 19 Fragment 21-1 Measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Elasticity Imaging Techniques,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Lymphangiography,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Ultrasonography,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,contralateral breast cancer,0.0,Female Breast Cancer
DIAGNOSES,Mammography,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
MEASURES,Nested Case-Control Studies,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Pathologic Examination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diffusion Kurtosis Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Subtyping,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Foundation for the Accreditation of Cellular Therapy,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Physicians,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Biomarker Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Practitioner,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Positron Emission Tomography and Magnetic Resonance Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Laboratory Procedures,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Immunoenzyme Procedure,Carcinoma breast stage I,0.0,Female Breast Cancer
DIAGNOSES,High resolution,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Epidermal Growth Factor Receptor Measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Mutagenesis Procedure,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,"Spectrum Analysis, Raman",Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,PD-L1 IHC 22C3 PharmDx,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Image quality analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diagnosis,Breast cancer stage III,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Radionuclide Imaging,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Flow Cytometry,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Conventional Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Traditional Healer,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Clinical Decision-Making,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Risk Analysis,Secondary malignant neoplasm of breast,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Genetic screening method,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
MEASURES,Cell Migration Assays,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Needle biopsy procedure,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Cell Count,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer
DIAGNOSES,Single-Cell Analysis,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Molecular Imaging,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,"Tomography, Emission-Computed",malignant neoplasm of breast staging,0.0,Female Breast Cancer
DIAGNOSES,Staining Intensity,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,Luminal B Breast Carcinoma,0.0039960039960039,Female Breast Cancer
DIAGNOSES,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,"Ultrasonography, Mammary",Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Polysomnography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Breast scan,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Breast Cancer Type 1 Susceptibility Protein Measurement,Basal-Like Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Photon Counting Computed Tomography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Fluorescent in Situ Hybridization,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
MEASURES,Immunofluorescence,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Paraffin Embedding,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Endoscopy of stomach,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Polymerase Chain Reaction,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Diagnostic Imaging,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,Polymerase Chain Reaction,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
MEASURES,Clinical Research,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,"Centrifugation, Density Gradient",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Staining method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Cortisol measurement, free, urine",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,"Spectrum Analysis, Raman",Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Autoradiography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Histology Procedure,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer
DIAGNOSES,Image analysis,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Xeromammography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Gel Electrophoresis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Cytometry,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,"Electrophoresis, Agar Gel",Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Physical breast examination,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Genetic screening method,Familial cancer of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Immunologic Tests,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Endoscopic biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Immunoperoxidase Techniques,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,"Immune complex assay, Raji cell",Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Cytophotometry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Radioimmunoassay,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
MEASURES,Flow Cytometry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Calcium measurement,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Carcinoembryonic antigen measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Orbital biopsy,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Periodic acid Schiff stain method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Measurement of serum lipid level,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Estrogen measurement, urine",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Fractionation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Radiography, Thoracic",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Sex hormone binding globulin measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Radioligand Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,G-Banding,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Tumor marker measurement,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Blood albumin,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Insurance broker,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Serum copper,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,"Autoradiography, Quantitative",Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Chromosome Mapping,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Polymerase Chain Reaction,Sporadic Breast Carcinoma,0.0009990009990009,Female Breast Cancer
DIAGNOSES,Film screen mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Doppler Ultrasound,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Staining method,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
MEASURES,Reverse Transcriptase Polymerase Chain Reaction,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Oncology Group,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,"Immunoassay, quantitative",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Metyrapone test,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Transillumination,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Assay,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
MEASURES,Medical Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Free thyroxine index test,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Author,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer
DIAGNOSES,Lymphocyte Count,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
MEASURES,Excision biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Polymerase chain reaction analysis,Sporadic Breast Carcinoma,0.0009990009990009,Female Breast Cancer
DIAGNOSES,In Situ Hybridization,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
MEASURES,Fluorescent in Situ Hybridization,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
MEASURES,Clinical Research,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Immunohistochemistry,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer
DIAGNOSES,"Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Sampling of lymph nodes NOS,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Artist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,DNA ploidy analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Clinical oncologist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Ultrasonography,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Electrophoresis,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
MEASURES,Immunocytochemistry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Serum vitamin D measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Insulin measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Urine level measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Differential Diagnosis,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,tomography,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
MEASURES,Magnetic Resonance Imaging,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
MEASURES,Scanning,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Breath Tests,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,research,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Eosinophil count procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Monocyte count procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Diagnosis, Computer-Assisted",Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
MEASURES,Homologous Recombination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Smooth Muscle Actin Staining Method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Surgical biopsy,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Routine chest X-ray,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Muscle biopsy,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
MEASURES,Quantitative Reverse Transcriptase PCR,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
MEASURES,Positron-Emission Tomography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Diagnosis, Computer-Assisted",Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,disease stage,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Doppler Ultrasound,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
MEASURES,"Blood Count, Complete",Contralateral breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Plasma prolactin measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,CALCULATION,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,Surgical biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Symptom checklist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,member,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,DNA analysis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Mucin-2 Staining Method,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Digital mammography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Computed radiography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,IMMUNOHISTOCHEMICAL,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
MEASURES,Core needle biopsy,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Diffusion Magnetic Resonance Imaging,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Co-Immunoprecipitation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Radionuclide Imaging,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Sentinel Lymph Node Biopsy,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
MEASURES,WORK UP,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Ultrasonography, Doppler","Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Polymerase Chain Reaction,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer
MEASURES,Magnetic Resonance Imaging,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,Ultrasonography,Breast cancer stage III,0.0029970029970029,Female Breast Cancer
MEASURES,Digital mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Mammography,bilateral breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Woman,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Spectroscopy,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Latex Fixation Tests,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Biopsy of ovary,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Physicist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Surgical biopsy,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Plasma arginine measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,QUICK METHOD,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,"Physicians, Women",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Genotype determination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Body mass index procedure,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Breast surgeon,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Creatinine clearance measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Genetic screening method,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Author,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,Diffusion weighted imaging,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Clinical Decision-Making,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Microarray Analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Family Study,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Screening procedure,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Punch biopsy (procedure),Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Immune Checkpoint Functional Assay,Luminal B Breast Carcinoma,0.0039960039960039,Female Breast Cancer
DIAGNOSES,Coculture Techniques,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Genetic screening method,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
MEASURES,Study,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Ultrasound examination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Gene Expression Profiling,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Quantitative Reverse Transcriptase PCR,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Body mass index procedure,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Iron binding capacity measurement,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,radiologist,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Ki67 Measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Positron Emission Mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,S-Phase Fraction,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Multiparametric Magnetic Resonance Imaging,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,FDG-Positron Emission Tomography and Computed Tomography Scan,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Diagnostic Neoplasm Staging,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Cell phenotype determination procedure,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Molecular Imaging,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Bone marrow biopsy,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,FLT-Positron Emission Tomography,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Monocyte Chemotactic Protein 1 Measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Breast Imaging Reporting and Data System,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Terahertz Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Cell Count,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Contrast enhanced spectral mammography,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Biopsy,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,PET/CT scan,Recurrent Breast Carcinoma,0.0019980019980019,Recurrent Breast Cancer
DIAGNOSES,Cytological Techniques,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Patients,HER2-negative breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Digital Mammography,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Genetic screening method,"Breast Cancer, Familial",0.0049950049950049,Female Breast Cancer
DIAGNOSES,New Target Lesion Identification,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Contrast-enhanced Magnetic Resonance Imaging,Multifocal breast carcinoma,0.0,Other
DIAGNOSES,Near-Infrared Fluorescence Imaging,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Wire-Guided Localization,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Circulating Tumor Cell Count,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Diffusion weighted imaging,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Psychometrics,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Breast Cancer Type 1 Susceptibility Protein Measurement,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,Functional assessment,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Core needle biopsy,Secondary malignant neoplasm of breast,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Body mass index procedure,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Cell Count,Basal-Like Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Measurement of serum amino acid level,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,thermal imaging,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,"Microscopy, Phase-Contrast",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diagnosis,Unilateral Breast Carcinoma,0.0,Female Breast Cancer
MEASURES,Mammography,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Gene Expression Profiling,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Single Photon Emission Computed Tomography Computed Tomography,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
MEASURES,Prospective Studies,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Point-of-Care Testing,Malignant neoplasm of female breast,0.0,Female Breast Cancer
DIAGNOSES,Medical pathologist,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,"Alpha-1-fetoprotein measurement, serum",Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
MEASURES,Contrast-Enhanced Mammography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,FDG-Positron Emission Tomography,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Sonographer,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Conventional Imaging,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Digital Breast Tomosynthesis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Diagnosis,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Ultrasonic Diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Cell Count,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Cell Count,Stage 0 Breast Cancer AJCC v6 and v7,0.0,Female Breast Cancer
DIAGNOSES,Diffusion weighted imaging,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Diffusion weighted imaging,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Survivors,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Immunophenotyping,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
MEASURES,Ultrasonography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Ki67 Measurement,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Tumor Burden,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Automated count,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,screen techniques,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Complete Blood Count,"Breast Cancer, Familial",0.0049950049950049,Female Breast Cancer
DIAGNOSES,Assay,"Breast Cancer, Familial",0.0049950049950049,Female Breast Cancer
DIAGNOSES,"Microscopy, Fluorescence",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Vitamin measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,mutation analysis,Familial cancer of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Scientist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Fibrinogen assay,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,enzyme linked immunospot assay,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,"Tomography, X-Ray",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Early Diagnosis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Engineer,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,proteomic profiling,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Study Section,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,"Angiography, Digital Subtraction",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Oral Glucose Tolerance Test,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Oxygen measurement, partial pressure, arterial",Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Plasma oestrogen,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,Plasma thyroid stimulating hormone,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Tissue culture,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Whole Body Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Semen liquefaction,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer
DIAGNOSES,"Copper measurement, serum",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,northern hybridization,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Calcium measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Surveys,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Plasma alkaline phosphatase NOS,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Sequence Analysis, DNA",Sporadic Breast Carcinoma,0.0009990009990009,Female Breast Cancer
DIAGNOSES,Plasma zinc measurement,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,breast cancer diagnosis,Contralateral breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Autopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Lymphocyte subset measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Serial scanning,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Image Cytometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Infrared photography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Blood count,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,rapid technique,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
MEASURES,Film Dosimetry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Mucin-1 Staining Method,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Writer,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Microdissection,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Cell Separation,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Immunology procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Ultrasonography, Doppler",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Image Cytometry,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Autoradiography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Sensitivity test,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Zinc measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Medical oncologist,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,HIGH SENSITIVITY,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Chromosome analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Histocytochemistry,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Mass Screening,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Intravenous digital subtraction angiography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,mutation analysis,Sporadic Breast Carcinoma,0.0009990009990009,Female Breast Cancer
DIAGNOSES,Restriction fragment length polymorphism analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Histocytochemistry,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Biopsy sampling,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Image Cytometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Surface Enhanced Laser Desorption Ionization Mass Spectrometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Endocrine function test,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Flow Cytometry,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Obstetrician,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Radioisotope scan of bone,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Research Personnel,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
MEASURES,Magnetic Resonance Spectroscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Microdissection,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Mass Fragmentography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Needle biopsy procedure,bilateral breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Biopsy of prostate,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Cell marker,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Immunoassay,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,fiber optic microscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Gene Expression Profiling,Familial cancer of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,TELOMERE ANALYSIS,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Medical pathologist,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Sample analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Biotinylation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Magnetic Resonance Imaging,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Observers,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Genetic screening method,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,Radioimmunoassay,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,Radioisotope scan of lymphatic system,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,blood flow measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Urine ratio,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Dual-Energy X-Ray Absorptiometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,MICROSCOPIC COUNT,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Assay,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Scanning,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Free prostate-specific antigen,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Tomography, Optical",Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Anesthesiologist,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,MANUAL COUNT,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Gene Expression Profiling,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Albumin/Globulin ratio,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Excision biopsy,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Tumor Burden,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
MEASURES,Radionuclide Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Tomography, Emission-Computed",Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,"Blotting, Western",Breast Carcinoma,0.0509490509490509,Female Breast Cancer
MEASURES,Western Blot,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,fluorodeoxyglucose positron emission tomography,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Tumor Burden,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Needle biopsy procedure,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Histocytochemistry,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer
DIAGNOSES,Medical Imaging,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
MEASURES,Image analysis,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Case Manager,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,genetic analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Body mass index procedure,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,"Diagnosis, Computer-Assisted",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Immunology profile,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Image analysis, quantitative",HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Light microscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Positron Emission Tomography and Magnetic Resonance Imaging,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
MEASURES,Quantitative Reverse Transcriptase PCR,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Intravital Microscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Tomography, Emission-Computed",Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Radioisotope scan of bone,Breast cancer stage II,0.0,Female Breast Cancer
DIAGNOSES,Echocardiography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diagnostic tests,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,"Ethics Committees, Research",Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Functional assessment,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,internal-external locus of control scale,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Ki67 Measurement,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,chromatin immunoprecipitation,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Breast Cancer Type 1 Susceptibility Protein Measurement,HER2-negative breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Seeding,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,tomography,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Microscopy,Triple-Negative Breast Carcinoma,0.0,Female Breast Cancer
DIAGNOSES,Estimated Glomerular Filtration Rate,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,PET/CT scan,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Platelet Count measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,serum estrogen,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Pathologic Examination,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Therapeutic evaluation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Sentinel Lymph Node Biopsy,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,High-B-Value Diffusion-Weighted Imaging,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Coculture Techniques,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Cell Count,"Breast Cancer, Familial",0.0049950049950049,Female Breast Cancer
DIAGNOSES,Transmission Electron Microscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Polymerase chain reaction analysis,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Biopsy,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer
DIAGNOSES,Mammography,malignant neoplasm of breast staging,0.0,Female Breast Cancer
DIAGNOSES,Observation - diagnostic procedure,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Mammography,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Surgeon,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,"Tomography, Emission-Computed, Single-Photon",Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Contrast used,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Assay,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,"Spectrum Analysis, Raman",Secondary malignant neoplasm of breast,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Red Blood Cell Count measurement,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Contrast-Enhanced Ultrasound,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Mammography,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Fine needle aspiration of breast,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Superb microvascular imaging,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Workers,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Optical Imaging,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,MRI guided biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Ki67 Measurement,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Diagnosis,Secondary malignant neoplasm of breast,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Conventional Imaging,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Decalcification Technique,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Immunoenzyme Procedure,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Positron Emission Tomography and Magnetic Resonance Imaging,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Plasminogen measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Subtyping,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Microbial susceptibility tests,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
MEASURES,Gene Expression Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Subtyping,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Dental Assistants,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Contrast-Enhanced Ultrasound,Papillary carcinoma of the breast,0.0009990009990009,Female Breast Cancer
DIAGNOSES,Breast Cancer Type 1 Susceptibility Protein Measurement,Triple-Negative Breast Carcinoma,0.0,Female Breast Cancer
DIAGNOSES,screening examination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Positron-Emission Tomography,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Gene Expression Profiling,Basal-Like Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Foundation for the Accreditation of Cellular Therapy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Chemical Exchange Saturation Transfer Magnetic Resonance Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Biopsy of skin procedure,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Cell Separation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Mammography,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer
DIAGNOSES,Laboratory Procedures,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Diffusion Tensor Imaging,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Contrast-Enhanced Ultrasound,Stage 0 Breast Cancer AJCC v6 and v7,0.0,Female Breast Cancer
DIAGNOSES,CA 15-3 measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Chemosensitivity Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Organism type determination procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Chromosome Banding,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Low ionic strength saline,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Bone marrow biopsy,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,"Toxicology screen, general","Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Indirect Immunofluorescence,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Serum oestrogen,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Image Cytometry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Serum zinc,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Immunohistochemistry,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,Bone Marrow Examination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,IMMUNOHISTOCHEMICAL,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer
MEASURES,Genetic Screening,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Carbohydrate antigen 549 measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Enzyme Tests,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Light microscopy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Dermatoglyphics,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Internist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,tomography,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,"Radiography, Thoracic",Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Serum cholinesterase,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Microscopy, Phase-Contrast",Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Tumor Stem Cell Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Research Design,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Bone marrow scintigraphy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Xeromammography,bilateral breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Karyotype determination procedure,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Radioisotope study of liver,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Copper measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Breast X-ray,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Chromosome analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,southern hybridization,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,mutation analysis,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,Quantitative Microscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,tomography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,comparative genomic analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Immunophenotyping,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Tissue culture,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Free thyroxine index test,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,comparative genomic analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Ultrasonic guidance procedure,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Cell phenotype determination procedure,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
MEASURES,Testing,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Quantitative sensory test,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Immunohistochemistry,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,"Protein concentration, test strip measurement",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Polymerase Chain Reaction,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,tissue processing,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,"Ethics Committees, Research",Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Cytology procedure,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
MEASURES,Ultrasonography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,infrared spectroscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,RNA Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Focus Groups,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Sentinel Lymph Node Biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Professional Organization or Group,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,comparative genomic analysis,bilateral breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Beta Catenin Staining Method,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Image analysis,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,"Spectrometry, Mass, Electrospray Ionization","Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,X-Ray Diffraction,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Analysis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,MANUAL COUNT,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Pseudothrombocytopenia,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Bilateral mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,IMMUNOHISTOCHEMICAL,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer
DIAGNOSES,Sentinel Lymph Node Mapping,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Lymph Node Mapping,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Silver Staining,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Whole-Body Scintigraphy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Mammogram - localization,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Immunoblotting,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Doppler Ultrasound,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,General surgeon,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Faculty, Medical",Breast cancer stage III,0.0029970029970029,Female Breast Cancer
DIAGNOSES,radiologist,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Drug measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Polymerase chain reaction analysis,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
MEASURES,Chemosensitivity Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Breast Self-Examination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Differential Diagnosis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Incisional biopsy - action,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Immunoradiometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,diagnostic procedure,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Mucin-2 Staining Method,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Diffusion weighted imaging,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Ultrasound examination,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
MEASURES,Clinical Research,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,Puncture biopsy,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Surgeon,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Fluorescent in Situ Hybridization,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer
DIAGNOSES,Cancer Diagnosis,Sporadic Breast Carcinoma,0.0009990009990009,Female Breast Cancer
DIAGNOSES,Digital mammography,bilateral breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,"Imaging, Three-Dimensional",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diagnostic Imaging,Contralateral breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,bilateral breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Ultrasonography,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
MEASURES,Multiphoton Microscopy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Biopsy,Recurrent Breast Carcinoma,0.0019980019980019,Recurrent Breast Cancer
DIAGNOSES,Biopsy,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
MEASURES,Immunohistochemistry,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Radionuclide Imaging,Stage IIA Breast Carcinoma,0.0,Other
DIAGNOSES,Cell Count,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Scientific Study,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,BRCA Mutation Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Real-Time Polymerase Chain Reaction,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Estimated Glomerular Filtration Rate,Basal-Like Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Assay,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer
DIAGNOSES,Ultrasonography,contralateral breast cancer,0.0,Female Breast Cancer
DIAGNOSES,Mammography,contralateral breast cancer,0.0,Female Breast Cancer
DIAGNOSES,Biopsy of skin procedure,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Cytological Techniques,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,Breast Cancer Type 1 Susceptibility Protein Measurement,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Patients,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
MEASURES,Colorimetric Cell Viability Assay,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
MEASURES,Psychometrics,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Elasticity Imaging Techniques,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,MRI brain procedure,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Contrast enhanced spectral mammography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Tumor Burden,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Alanine measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diagnostic Imaging,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Immunohistochemistry,Secondary malignant neoplasm of breast,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Biopsy,Triple-Negative Breast Carcinoma,0.0,Female Breast Cancer
DIAGNOSES,"Tomography, Emission-Computed",Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Ultrafast MRI,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Attendants -- group,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Lymphocyte to C-Reactive Protein Ratio Measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Subtyping,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
MEASURES,Consensus Clustering,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Absolute lymphocyte count,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,medical diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Immunophenotyping,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,FDG-Positron Emission Tomography and Computed Tomography Scan,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,CA 125 measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Punch biopsy (procedure),Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,tomography,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,X-Ray Computed Tomography,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,FDG-Positron Emission Tomography,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Positron-Emission Tomography,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Conventional Imaging,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Work-up,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Ki67 Measurement,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Examination of breast,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Positron Emission Tomography and Magnetic Resonance Imaging,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Protein Expression Analysis,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Ultrasonography,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,community leader,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Multiphoton Microscopy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Positron Emission Mammography,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,"Physical Therapist - Electrophysiology, Clinical",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Diagnostic assessment,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Early Diagnosis,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,Biopsy of skin procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Biochemical test,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Image Cytometry,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Physicians,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Scintiphotography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Mass Screening,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer
DIAGNOSES,Radioisotope scan of bone,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
MEASURES,Histocytochemistry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Progesterone measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Nucleic acid analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Indium Scan,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Radioimmunoassay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Genetic screening method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Gel Electrophoresis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
MEASURES,Radioimmunoassay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,HEART STUDY,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Doppler Ultrasound,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Histology Procedure,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Carcinoembryonic antigen measurement,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Cell Culture Techniques,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,In Situ Hybridization,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,"Microscopy, Confocal, Laser Scanning",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Geneticist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Physicians,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Western Blot,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Glomerular Filtration Rate,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Puncture biopsy,bilateral breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,DNA chemical synthesis,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
MEASURES,Biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diagnostic assessment,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,enzyme linked immunospot assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Microscopy, Video",Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Radionuclide Imaging,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,Liquid Chromatography Mass Spectrometry,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Policy Makers,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Orbital biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Spectrum Analysis,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Pharmacokinetic study,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Biopsy of skin procedure,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,"Tomography, Optical Coherence",Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Miller,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,"Transport Media,",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Blood Count, Complete",Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Genetic screening method,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer
DIAGNOSES,Microscopic observation,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Genetic Screening,Familial cancer of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Biopsy,bilateral breast cancer,0.0019980019980019,Female Breast Cancer
MEASURES,"Diagnosis, Computer-Assisted",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Immunohistochemistry,Familial cancer of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,D-lactate measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Light microscopy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Human papillomavirus DNA detection,Sporadic Breast Carcinoma,0.0009990009990009,Female Breast Cancer
MEASURES,Liquid Chromatography Mass Spectrometry,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Incisional biopsy - action,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
MEASURES,Assay,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,fluorodeoxyglucose positron emission tomography,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Immunohistochemistry,Lobular carcinoma in situ of breast,0.0,Female Breast Cancer
DIAGNOSES,Immunofluorescence,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Morphometric analysis,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer
DIAGNOSES,Sampling of lymph nodes NOS,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Cytokeratin-14 Staining Method,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,Consultant,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,"Tomography, Spiral Computed",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Palpation,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,Clinicians,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Karyotype determination procedure,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Cytokeratin-14 Staining Method,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Interleukin level,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Image analysis, quantitative",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Plastic surgeon,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Polymerase Chain Reaction,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,"Tomography, Optical Coherence",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Magnetic Resonance Imaging,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
MEASURES,spatial data analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,tomography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,neuroimaging,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,C-reactive protein measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Chest physician,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Exercise stress test,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,diagnostic procedure,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Community Workers,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Specimen mammography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Liquid Chromatography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Smooth Muscle Actin Staining Method,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Nucleic acid assay,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Activated clotting time measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Sentinel Lymph Node Biopsy,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Electrophoretic Mobility Shift Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Family member,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Blotting, Western",Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Biopsy,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Occupational physician,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Diagnosis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Diagnosis,HER2-negative breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Positron-Emission Tomography,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Sequence Analysis,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Contrast-Enhanced Ultrasound,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Image Study,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Immunohistochemistry,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Assay,Triple-Negative Breast Carcinoma,0.0,Female Breast Cancer
DIAGNOSES,Radioisotope scan of bone,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Needle biopsy procedure,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
MEASURES,Prosigna Breast Cancer Prognostic Gene Signature Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Near-Infrared Fluorescence Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Magnetic resonance imaging of breast,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Complement C1q binding,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Autoradiography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Microarray Analysis,Basal-Like Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Screening procedure,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer
DIAGNOSES,Oncologists,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,3D COMPUTERIZED TOMOGRAPHY,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Genetic screening method,HER2-negative breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Immunohistochemistry,Triple-Negative Breast Carcinoma,0.0,Female Breast Cancer
DIAGNOSES,Chemokine (C-X-C Motif) Ligand 10 Measurement,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Assay,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer
DIAGNOSES,radiologist,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,High resolution,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Microarray Analysis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Punch biopsy (procedure),Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Mutagenesis Procedure,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,In Vivo Imaging,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,MRI Scans,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Immunoglobulin G Subclass 4 Measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Oncologists,HER2-negative breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,DNA Maintenance,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Digital Breast Tomosynthesis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Contrast enhanced spectral mammography,Multifocal breast carcinoma,0.0,Other
DIAGNOSES,heart study,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Seeding,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Core needle biopsy,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Orbital B scan,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Alpha tumour necrosis factor measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,"Microscopy, Atomic Force",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Assay,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Biopsy of skin procedure,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Chiropractor,Recurrent Breast Carcinoma,0.0019980019980019,Recurrent Breast Cancer
DIAGNOSES,Immunologic Techniques,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Core needle biopsy,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Laboratory Procedures,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Ultrasonography,HER2-negative breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Computer assisted method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Embedding,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Cell function assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Ki67 Measurement,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer
DIAGNOSES,Mammography,Stage IIIB Breast Carcinoma,0.0,Other
DIAGNOSES,Ultrasound elastography,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Whole body bone imaging (procedure),Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,FDG-Positron Emission Tomography and Computed Tomography Scan,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Biological Assay,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,High resolution,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,CA 125 measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Plasma lipid measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Reflection illumination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Biopsy,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Author,Carcinoma breast stage I,0.0,Female Breast Cancer
DIAGNOSES,digital tomosynthesis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Tomography, Emission-Computed",HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,PET/CT scan,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Nurses,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
MEASURES,Assay,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Merging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Observation - diagnostic procedure,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,Image Study,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Magnetic resonance imaging of breast,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,B mode ultrasound,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Differential panel,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Spinal Puncture,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,CA 19-9 measurement,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer
DIAGNOSES,"Tomography, Emission-Computed",Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Serum protein electrophoresis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Serum prolactin measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,RAPID TEST,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Study Section,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Neutralization,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Fine needle aspiration biopsy,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,Steroid activity,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Immunoblotting,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Plasma calcitonin level,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Estrogen receptor assay (ERA),Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Serum selenium measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Radioisotope scan of lymphatic system,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Physical assessment,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Densitometry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,C1q binding assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Morphometric analysis,Breast cancer stage III,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Serum ferritin measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
MEASURES,End Point,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Serum cholesterol measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,thermography,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Microscopy,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer
DIAGNOSES,buccal smear biopsy procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,southern hybridization,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Specimen collection,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Serum riboflavine measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,two-dimensional electrophoresis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Mammography,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Morphometric analysis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,"Protein concentration, test strip measurement",Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Radiographic imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,comparative genomic analysis,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Drug measurement,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,Prostate specific antigen measurement,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Laparoscopy with biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Tumor marker measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Ultrasound examination,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
MEASURES,Comparative Genomic Hybridization,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Anti-SS-B antibody,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Electrophoresis, Polyacrylamide Gel",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Reverse Transcriptase Polymerase Chain Reaction,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Multimodal Imaging,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
MEASURES,"Spectrum Analysis, Mass",Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Sequence Analysis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Chromogenic in situ Hybridization,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Mean cell hemoglobin measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Tissue Array Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,thermography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Author,Carcinoma in situ of breast,0.0,Female Breast Cancer
DIAGNOSES,Health Personnel,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Committee Members,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Reader,Breast cancer stage III,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Biopsy of skin procedure,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,"Spectrum Analysis, Mass",Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,Family investigation,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Oncologist,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,Dermatoglyphics,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Spectrum Analysis,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Interferometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Midwife,Familial cancer of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Cytokeratin-8 Staining Method,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Enzyme-Linked Immunosorbent Assay,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Chest imaging,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,American,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Spectrum Analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,single cell analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Examination of breast,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Pharmacokinetic study,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Cytophotometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Oncologist,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Autoantibody measurement,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Diffusion weighted imaging,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Clinicians,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Diffusion Magnetic Resonance Imaging,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,endoscopy,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer
DIAGNOSES,Employer,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Ultrasonography,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer
DIAGNOSES,Tumor Burden,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,"Ultrasonography, Mammary",Breast Carcinoma,0.0509490509490509,Female Breast Cancer
MEASURES,univariate analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Ultrasonography, Doppler",Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
MEASURES,Random Allocation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Endoscopic biopsy,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Scanning,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,CA 15-3 measurement,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer
DIAGNOSES,Needle biopsy procedure,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer
MEASURES,Fluorescent in Situ Hybridization,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer
DIAGNOSES,Nuclear magnetic resonance imaging whole body,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Clinical Research,Contralateral breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Physical breast examination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,WORK UP,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Breast Self-Examination,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
MEASURES,Gene Expression Profiling,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,medical specialist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Phase contrast,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Cell Count,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer
DIAGNOSES,Nutrition Assessment,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,The Cancer Genome Atlas,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Caregiver,malignant neoplasm of breast staging,0.0,Female Breast Cancer
MEASURES,Differential panel,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
MEASURES,Computer Assisted Diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Screening procedure,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Fatty Liver Index,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Infrared spectroscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Complete Blood Count,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,tomography,Breast cancer stage II,0.0,Female Breast Cancer
DIAGNOSES,Positron-Emission Tomography,Breast cancer stage II,0.0,Female Breast Cancer
DIAGNOSES,Author,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Magnetic Resonance Imaging,Breast cancer stage II,0.0,Female Breast Cancer
DIAGNOSES,Reporter (occupation),Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Laboratory Procedures,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
MEASURES,Assay,Basal-Like Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Pyrosequencing,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Arginine measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Mammogram - symptomatic,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Red Cell Fatty Acid Profile,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Laboratory Procedures,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Monocyte count procedure,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Contrast-Enhanced Mammography,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Electrophysiology studies,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Quantitative PCR analysis,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Excision biopsy,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,T4 free measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Genetic screening method,Stage 0 Breast Cancer AJCC v6 and v7,0.0,Female Breast Cancer
DIAGNOSES,Fluorescent Antibody Technique,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Laparoscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Initial Diagnosis,Stage 0 Breast Cancer AJCC v6 and v7,0.0,Female Breast Cancer
DIAGNOSES,Red cell distribution width determination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Ultrasonography,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Chef,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer
DIAGNOSES,Gate-keeper,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
MEASURES,Data Collection,contralateral breast cancer,0.0,Female Breast Cancer
DIAGNOSES,Screening for cancer,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Nucleic acid sequencing,"Breast Cancer, Familial",0.0049950049950049,Female Breast Cancer
DIAGNOSES,Clinician,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Body mass index procedure,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Biopsy,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
MEASURES,"Tomography, Optical Coherence",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Mass Spectrometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Core needle biopsy,Lobular carcinoma in situ of breast,0.0,Female Breast Cancer
DIAGNOSES,Transient elastography,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Percutaneous Breast Biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Sulfate measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Diagnosis,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer
MEASURES,Study,Breast Carcinoma,0.0509490509490509,Female Breast Cancer
DIAGNOSES,Leukemia Inhibitory Factor Measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Radioisotopic Labeling (lab procedure),Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Examination by method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Multimodal Imaging,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Ultrasound-Guided Fine-Needle Aspiration,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Fluorescence Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Restriction Spectrum Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,"Tomography, Emission-Computed",estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Electroporation,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,Pegylation,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Serum Triglyceride Measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
MEASURES,Statistical Technique,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Methionine measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,FDG-Positron Emission Tomography and Computed Tomography Scan,Metastatic Breast Carcinoma in the Skin,0.0,Other
DIAGNOSES,Diagnosis,Basal-Like Breast Carcinoma,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Diffuse Optical Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Clinician,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Substance Abuse Detection,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
MEASURES,Magnetic resonance imaging of breast,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Histological Techniques,Primary malignant neoplasm of breast with axillary lymph node invasion,0.0,Other
DIAGNOSES,Contrast-Enhanced Ultrasound,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer
DIAGNOSES,Initial Diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Classic tomography,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer
DIAGNOSES,Work-up,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer
DIAGNOSES,Optical Imaging,Secondary malignant neoplasm of breast,0.0049950049950049,Female Breast Cancer
DIAGNOSES,Patient Navigators,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer
DIAGNOSES,Ultrafast MRI,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer
DIAGNOSES,Diagnostic Imaging,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer
DIAGNOSES,Transient elastography,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer
DIAGNOSES,FDG-Positron Emission Tomography,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer
DIAGNOSES,Multiparametric Magnetic Resonance Imaging,Luminal B Breast Carcinoma,0.0039960039960039,Female Breast Cancer
